SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor
activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06285422.
This is an open-label, single arm, Phase 1, first-in-human (FIH) study to evaluate the
safety and tolerability of SC262 administered intravenously (IV) following a standard
lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine in subjects with
Non Hodgkin's Lymphoma (NHL) who have received no more than 1 prior CD19-directed
Chimeric Antigen Receptor T-Cells (CAR T) cell therapy. This study will be conducted in 2
parts. Dose finding using a 3+3 design in subjects with NHL. Dose expansion to further
evaluate safety and efficacy at the recommended phase 2 dose (RP2D) in subjects with
Large B-Cell Lymphoma (LBCL).
Lead OrganizationSana Biotechnology
Principal InvestigatorPaul Brunetta
